ARMP Latest Press Releases

-- July 20, 2026 --

Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 PRNewswire 7:00 AM

-- July 13, 2026 --

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia PRNewswire 7:00 AM

-- June 23, 2026 --

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 PRNewswire 7:00 AM

-- May 13, 2026 --

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update PRNewswire 4:30 PM

-- May 7, 2026 --

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 PRNewswire 7:00 AM

-- May 4, 2026 --

Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" PRNewswire 7:00 AM

-- April 27, 2026 --

Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors PRNewswire 7:00 AM

-- March 25, 2026 --

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results PRNewswire 4:05 PM

-- March 19, 2026 --

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update PRNewswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software